ORCID as entered in ROS

Select Publications
2024, 'Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research, MA, Boston, 15 September 2024 - 18 September 2024, http://dx.doi.org/10.1158/1538-7445.PANCREATIC24-A067
,2024, 'Combining zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, Vol. 84, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2024 - 10 April 2024, http://dx.doi.org/10.1158/1538-7445.AM2024-720
,2024, 'Selective targeting of integrins αVβ8 and αVβ1 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, Vol. 84, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2024 - 10 April 2024, http://dx.doi.org/10.1158/1538-7445.AM2024-6575
,2024, '1513P Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S925 - S925, http://dx.doi.org/10.1016/j.annonc.2024.08.1576
,2023, 'Anti-fibrotic FAK 'priming' to improve contemporary chemotherapy in pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 27 September 2023 - 30 September 2023, http://dx.doi.org/10.1158/1538-7445.PANCA2023-B037
,2023, 'Re-purposing non-oncology agent itraconazole to target the dynamic cellular ecosystem of pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 27 September 2023 - 30 September 2023, http://dx.doi.org/10.1158/1538-7445.PANCA2023-A029
,2023, 'The anti-fungal itraconazole improves immunotherapy efficacy in pancreatic ductal adenocarcinoma by reversing the immune-suppressive tumor microenvironment', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 27 September 2023 - 30 September 2023, http://dx.doi.org/10.1158/1538-7445.PANCA2023-C017
,2022, 'EFFECTIVE CO-TARGETING OF FIBROTIC AND IMMUNE MICROENVIRONMENTS TO IMPROVE THE OVERALL ANTI-TUMOUR RESPONSE IN MODELS OF ADVANCED PANCREATIC CANCER', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, Vol. 10, pp. A1514 - A1514, http://dx.doi.org/10.1136/jitc-2022-SITC2022.1455
,2017, 'Effect of Rho/ROCK pathway inhibition on metastasis-free and overall survival in biomarker selected, orthotopic, patient-derived models of pancreatic cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e15759
,2015, 'Targeting the Rho-ROCK pathway to treat pancreatic cancer: The use of unique preclinical models to ascertain the effects on cancer growth and metastasis', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 33, presented at Gastrointestinal Cancers Symposium, CA, San Francisco, 15 January 2015 - 17 January 2015, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.312
,2013, 'From functional genomics to precision medicine: The therapeutic potential of targeting ROCK signaling in pancreatic cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603693&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Risk factors for pancreatic cancer in patients with and without a family history of pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, Vol. 27, pp. 127 - 127, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Proffered Paper: Testing Individualised Treatment Strategies in Preclinical Models of Pancreatic Cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, Barcelona, Vol. 48, pp. S22 - S22, presented at 22nd Biennial Congress of the European-Association-for-Cancer-Research, SPAIN, Barcelona, 07 July 2012 - 10 July 2012, http://dx.doi.org/10.1016/S0959-8049(12)70795-5
,2006, 'Sensitisation of neuroblastorna tumours to chemotherapy by use of a novel class of MRP1 small molecule inhibitor', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 54 - 54, http://dx.doi.org/10.1016/S1359-6349(06)70175-6
,